Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib

OBJECTIVE: A survival benefit was demonstrated for ramucirumab (RAM) in patients with unresectable hepatocellular carcinoma (uHCC) and α-fetoprotein (AFP) concentrations ≥400 ng/mL who had previously received sorafenib (SOR). However, it is unclear whether RAM has a similar efficacy in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasuya, Kayoko, Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Kajiwara, Akira, Iritani, Soichi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Eguchi, Yuichiro, Hashimoto, Masaji, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925279/
https://www.ncbi.nlm.nih.gov/pubmed/32963154
http://dx.doi.org/10.2169/internalmedicine.5185-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925279/
https://www.ncbi.nlm.nih.gov/pubmed/32963154
http://dx.doi.org/10.2169/internalmedicine.5185-20

Ejemplares similares